The COVID-19 pandemic has led to an exponential
increase in SARS-CoV-
2 infections and associated deaths,
and represents a significant challenge to healthcare
professionals and facilities. Individual countries have
taken several prevention and containment actions to
control the spread of infection, including measures
to guarantee safety of both healthcare professionals
and patients who are at increased risk of infection
from COVID-19. Faecal microbiota transplantation
(FMT) has a well-established
role in the treatment
of Clostridioides difficile infection. In the time of the
pandemic, FMT centres and stool banks are required
to adopt a workflow that continues to ensure reliable
patient access to FMT while maintaining safety and
quality of procedures. In this position paper, based on the
best available evidence, worldwide FMT experts provide
guidance on issues relating to the impact of COVID-19
on FMT, including patient selection, donor recruitment
and selection, stool manufacturing, FMT procedures,
patient follow-up
and research activities